Anemo Labs provides an electronic olfactory sensor platform that non‑invasively detects volatile organic compounds in urine, sweat and other bodily fluids. The device uses an array of engineered receptors on an olfactory chip and AI‑driven pattern recognition to translate scent signatures into health biomarkers, delivering rapid, low‑cost screening and continuous monitoring for healthcare providers and wellness companies.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including cancers, are diagnosed only after symptoms appear, limiting the window for effective early intervention. Current biomarker testing often requires invasive, expensive procedures, making frequent monitoring impractical for routine health management.
Solution
Anemo Labs offers an electronic olfactory sensor platform that non‑invasively detects volatile organic compounds (VOCs) in urine, sweat, and other bodily fluids. The device incorporates an array of hundreds of synthetic receptors on an olfactory chip, enabling parallel detection of dozens of unique air molecules. Collected scent signatures are processed by AI models trained on extensive smell pattern datasets to identify health‑related biomarkers. This approach provides rapid, low‑cost screening and continuous health monitoring without the need for needles or laboratory visits. Results can be delivered to clinicians or users via a digital interface, supporting earlier detection of disease signals across multiple health indicators.
Target Audience
Primary customers are healthcare providers, diagnostic laboratories, and wellness companies seeking affordable, non‑invasive screening tools for early disease detection and ongoing health monitoring.
Features
- Olfactory chip with hundreds of engineered receptors for parallel VOC detection
- AI‑driven pattern‑recognition engine that maps scent profiles to specific health biomarkers
- Compatibility with urine, sweat, and other non‑invasive fluid samples
- Portable, electronic “electronic nose” hardware designed for point‑of‑care or at‑home use
- Real‑time data transmission to cloud analytics for rapid result generation
- Scalable architecture allowing expansion to additional disease panels as new biomarkers are discovered